"The U.S. Food and Drug Administration today approved the Gastric Emptying Breath Test (GEBT), a new non-invasive test to aid in the diagnosis of delayed gastric emptying, known as gastroparesis.
Current tests used to diagnose gastroparesis "...
Mild to moderate adverse reactions have been noted for synthetic human secretin in clinical studies in 533 patients and 51 healthy volunteers. Two severe adverse reactions, nausea and abdominal pain, occurred in one patient. Table 1 details the type and number of patients with adverse reactions.
TABLE 1 ADVERSE REACTIONS WITH CHIRHOSTIM® (human secretin)
|Adverse Reaction|| N = 584
|Early removal of Dreiling tube||3 (3)|
|Abdominal pain||3 (3)|
|Increased heart rate||2 (2)|
|Mild Pancreatitis||2 (2)|
|Upset stomach||2 (2)|
|Burning in stomach or abdomen||1 (1)|
|Clammy skin||1 (1)|
|Decreased O2 saturation||1 (1)|
|Infiltrated IV||1 (1)|
|Oral secretions increased||1 (1)|
|Slow heart rate (57 bpm)||1 (1)|
|Tingling in legs||1 (1)|
|Warm sensation in abdomen||1 (1)|
|Warm sensation in face||1 (1)|
Of the 584 patients and healthy volunteers treated with ChiRhoStim® (human secretin) , a total of 29 patients (5%) had at least one adverse reaction.
Read the ChiRhoStim (human secretin) Side Effects Center for a complete guide to possible side effects
The concomitant use of anticholinergic agents may make patients hyporesponsive to secretin stimulation and may produce a false result. Any results of secretin stimulation tests in these patients should thus be interpreted with caution.
Last reviewed on RxList: 7/17/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional ChiRhoStim Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.